Cell Line Development Services for Brain Tumors
The establishment of reliable and reproducible cell lines from these tumors is vital for preclinical studies, drug discovery, and the development of targeted therapies. Alfa Cytology specializes in comprehensive cell line development services tailored for brain tumor research.
Introduction to Brain Tumor Cell Line Models
The complexity of brain tumors, including glioblastomas and lower-grade gliomas, demands sophisticated models for effective research and therapeutic development. Cell line models serve as essential tools in cancer research, providing insights into tumor biology, drug response, and the molecular mechanisms underlying tumor progression. However, traditional cell lines often lack the genetic and phenotypic diversity found in primary tumors, leading to suboptimal translational outcomes.
Fig.1 In vitro models using glioma stem cells (GSCs) for glioma immunological research. (Park, J.H., et al., 2024)
Our Services
At Alfa Cytology, we specialize in developing high-fidelity brain tumor cell lines that closely mimic the original tumor microenvironment. By utilizing patient-derived cells and advanced genetic engineering techniques, our models are better equipped to replicate the heterogeneity and complexity of brain tumors. This approach enhances the reliability of preclinical studies and facilitates the discovery of novel therapeutic targets.
Reporter Cell Line Construction Services
Alfa Cytology customizes the development of reporter gene functional cell lines to meet customer needs. It can eliminate the need for primary cell culture and overcome the limitations of traditional methods and is suitable for large-scale high-throughput brain tumor antibody drug screening, bioactivity assay, and stability determination.
Stable Cell Line Construction Services
Alfa Cytology screens target cells for resistance markers on a transient transfection basis. Alternatively, high transfection efficiency viruses are used to select the appropriate drugs for cell passaging according to the resistance markers contained in the different gene vectors. This results in cell lines that can stably express the target gene in a short period.
Stem Cell Development Services
Alfa Cytology provides brain tumor stem cell development methods and analysis services that can explain the differentiation path of brain tumor stem cells, help you develop newer brain tumor treatment strategies, and accelerate research on brain tumor growth, dissemination, recurrence, targeted therapeutic approaches, etc.
Case Study - U-87 MG Xenograft Model in C-NKG & NOD-Scid Mice
Model Introduction
The U-87 MG human glioblastoma xenograft model provides a validated preclinical platform for studying glioblastoma growth and therapeutic response. U-87 MG is a human glioblastoma cell line derived from malignant gliomas. It is extensively utilized in oncology research to investigate glioblastoma biology and evaluate novel therapeutic approaches due to its aggressive growth characteristics and relevance to central nervous system tumors.
Model Information
- Model: U-87 MG Xenograft Model
- Animals: C-NKG Mice; NOD-Scid Mice
- Age: 7 Weeks
Model Construction
The model was established by subcutaneously implanting human U-87 MG glioblastoma cells into mice. Tumor growth is monitored regularly by caliper measurements to track progression. Cell inoculum is 3×106 cells/mouse for both C-NKG and NOD-Scid strains.
Fig. 2 Workflow of U-87 MG xenograft model establishment. (Source: Alfa Cytology)
Model Data
- Tumorigenicity: U-87 MG cells demonstrate high tumorigenic potential in both C-NKG and NOD-Scid mouse strains, with easy and consistent model establishment.
- Growth Kinetics: Tumor growth is measurable and progressive. Approximately 9 days post-inoculation, tumors reach 100-200 mm3, which is suitable for initiating treatment. By around day 38, tumors approach the experimental endpoint volume of ~2000 mm3.
- Therapeutic Window: The model provides a clear treatment observation window of approximately 29 days, ideal for efficacy evaluation during the tumor growth phase.
Fig. 3 Growth curves of U-87 MG subcutaneous xenograft tumors and mouse body weight in C-NKG and NOD-Scid mice (n=6). Data are expressed as mean ± SEM. (Source: Alfa Cytology)
Contact Us
Alfa Cytology is committed to providing top-tier cell line development services. Our team of experts is ready to assist you at every step of the process. To learn more about our services or to discuss your specific research needs, please feel free to contact us.
Reference
- Park J. H., et al. (2024) Vaccine-based immunotherapy and related preclinical models for glioma[J]. Trends in Molecular Medicine. 30, 10, 965 - 981.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
